Osteoprotegerin (OPG) levels, total soluble receptor activator of nuclear factor-Kappa B ligand (total sRANKL) , and RANKL/OPG ratio in patients with rheumatoid arteritis

Publish Year: 1396
نوع سند: مقاله ژورنالی
زبان: English
View: 348

This Paper With 7 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_RHRE-2-1_004

تاریخ نمایه سازی: 1 خرداد 1398

Abstract:

Rheumatoid arthritis (RA) is one of most important collagen vascular diseases. It has an unknown origin. The aim of this study was to evaluate circulating levels of osteoprotegerin (OPG), total soluble receptor activator of nuclear factor-Kappa B ligand (total sRANKL), and RANKL/OPG ratio in patients with RA. Forty-five females with RA, who fulfilled the American college of rheumatology (ACR) criteria for RA were included in this cross-sectional study. The overall disease activity was evaluated by the disease activity score based on 28 joint counts (DAS-28). The OPG and sRANKL were measured by the enzyme-linked immunosorbent assays (ELISA). The levels of C-reactive protein (CRP) were measured by ELISA.We used Pearson’s correlation for our comparisons. There was no statistically significant difference between the levels of CRP, OPG, sRANKL and RANKL/OPG ratio in terms of DAS-28 grades in our patients. No significant correlation was found between the serum levels of OPG and DAS-28 (P= 0.525), duration of the disease (P= 0.884), Z-score of the femur (P= 0.546) and Z-score of the spine (P= 0.492), T-score of the femur (P= 0.137) and T-score of the spine (P= 0.821) in the patient group. No significant correlations were found between sRANKL levels with DAS-28 (0.919), Z-score of the femur (P= 0.971), Z-score of the spine (P= 0.832) and T-score of the femur (P = 0170) in the studied groups. Our study showed that there was no significant correlation between CRP, OPG, sRANKL and RANKL/OPG ratio in DAS-28 grading of our patients. For this reason they will not be used for evaluating disease activity. However, there was a significant difference between case and control groups except for sRANKL (pg/mL).

Authors

Sousan Kolahi

Drug Applied Research Center, Connective Tissue Diseases Research Center, Department of Rheumatology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Amir Ghorbanihaghjo

Drug Applied Research Center, Connective Tissue Diseases Research Center, Department of Biochemistry, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Nadereh Rashtchizadeh

Drug Applied Research Center, Connective Tissue Diseases Research Center, Department of Biochemistry, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Alireza Khabbazi

Drug Applied Research Center, Connective Tissue Diseases Research Center, Department of Rheumatology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Carlsen H, Moskaug JO, Fromm SH, Blomhoff R. In vivo ...
  • Gal I, Bajnok E, Szanto S, Sarraj B, Glant TT, ...
  • Amaya-Amaya J, Sarmiento-Monroy JC, Mantilla RD, Pineda-Tamayo R, Rojas-Villarraga A, ...
  • Fiehn C. [Rheumatoid arthritis - cardiovascular risk is high, but ...
  • Ozbalkan Z, Efe C, Cesur M, Ertek S, Nasiroglu N, ...
  • Bijl M. Endothelial activation, endothelial dysfunction and premature atherosclerosis in ...
  • Paccou J, Brazier M, Mentaverri R, Kamel S, Fardellone P, ...
  • Rho YH, Chung CP, Oeser A, Solus J, Asanuma Y, ...
  • Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy ...
  • Tanaka Y. [Rheumatoid arthritis and osteoporosis: trends in theirtreatments]. Nihon ...
  • Strand V, Kavanaugh AF. The role of interleukin-1 in bone ...
  • Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear ...
  • Jorgensen C. Mesenchymal stem cells in arthritis: role of bone ...
  • Walsh NC, Gravallese EM. Bone remodeling in rheumatic disease: a ...
  • Fili S, Karalaki M, Schaller B. Therapeutic implications of osteoprotegerin. ...
  • Leibbrandt A, Penninger JM. RANKL/RANK as key factors for osteoclast ...
  • Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling ...
  • Fu Q, Jilka RL, Manolagas SC, O’Brien CA. Parathyroid hormone ...
  • Spelling P, Bonfa E, Caparbo VF, Pereira RM. Osteoprotegerin/ RANKL ...
  • Wasilewska A, Rybi-Szuminska AA, Zoch-Zwierz W. Serum osteoprotegrin (OPG) and ...
  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, ...
  • Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, ...
  • Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. ...
  • Klejna K, Naumnik B, Gasowska K, Mysliwiec M. OPG/ RANK/ ...
  • Gaudio A, Lasco A, Morabito N, Atteritano M, Vergara C, ...
  • Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear ...
  • Tat SK, Padrines M, Theoleyre S, Couillaud-Battaglia S, Heymann D, ...
  • Nakamura H, Kumei Y, Morita S, Shimokawa H, Ohya K, ...
  • Kobayashi-Sakamoto M, Hirose K, Nishikata M, Isogai E, Chiba I. ...
  • Wallin R, Wajih N, Greenwood GT, Sane DC. Arterial calcification: ...
  • Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, ...
  • Anand DV, Lim E, Darko D, Bassett P, Hopkins D, ...
  • Breland UM, Hollan I, Saatvedt K, Almdahl SM, Damas JK, ...
  • Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, ...
  • Gonzalez-Alvaro I, Ortiz AM, Tomero EG, Balsa A, Orte J, ...
  • Xu S, Wang Y, Lu J, Xu J. Osteoprotegerin and ...
  • Ueland T, Bollerslev J, Wilson SG, Dick IM, Islam FM, ...
  • Bezerra MC, Calomeni GD, Caparbo VF, Gebrim ES, Rocha MS, ...
  • Zupan J, Jeras M, Marc J. Osteoimmunology and the influence ...
  • نمایش کامل مراجع